3696-23-9

Usage

Uses

Used in Pharmaceutical Industry:
4-CHLOROPHENYLTHIOUREA is used as an intermediate in the synthesis of N-(4-Chlorophenyl)-O-methylisourea Sulfate Salt (~90%) (C378465), which is a cytotoxic agent. This cytotoxic agent exhibits tumor inhibitory activity, making it a valuable component in the development of cancer treatments.

InChI:InChI=1/C7H7ClN2S/c8-5-1-3-6(4-2-5)10-7(9)11/h1-4H,(H3,9,10,11)

Upstream product

• 4921-83-9 1-benzoyl-3-(4-chloro-phenyl)-thiourea 
• 2131-55-7 4-Chlorophenyl isothiocyanate 
• 14327-08-3 1-tert-butyl-3-(4-chlorophenyl)thiourea 
• 333-20-0 potassium thioacyanate 
• 106-47-8 4-chloro-aniline 
• 1147550-11-5 ammonium thiocyanate 
• 43009-19-4 p-chlorophenyldithiocarbamic acid triethylamine salt 
• 20265-96-7 p-chloroaniline hydrochloride 
• 17356-08-0 thiourea 
• 52077-66-4 ethyl N-[(4-chlorophenyl)carbamothioyl]carbamate 
• 540-72-7 sodium thiocyanide 
• 13463-94-0 N-(4-chlorophenyl)cyanamide 
• 106-46-7 para-dichlorobenzene 
• 162101-10-2 N-(4-chloro-phenylthiocarbamoyl)-S-methyl-isothiourea 

Downstream Products

• 99183-83-2 3-(4-chloro-phenyl)-4-methyl-3H-thiazol-2-one-imine 
• 51039-92-0 (4-chloro-phenyl)-(4-methyl-thiazol-2-yl)-amine 
• 21262-23-7 2-(4-chloro-anilino)-thiazol-4-one 
• 92428-10-9 N-(4-chlorophenyl)-4-phenylthiazol-2-amine 
• 39536-21-5 S-methyl N-(4-chlorophenyl)amidino thioether 
• 31200-22-3 3-(4-chloro-phenyl)-3H-thiazolo[4,5-b]quinoxalin-2-ylideneamine 
• 31102-66-6 (4-chloro-phenyl)-thiazolo[4,5-b]quinoxalin-2-yl-amine 
• 54819-69-1 2-[2-(4-chloro-anilino)-4-oxo-4,5-dihydro-thiazol-5-yl]-N-(4-chloro-phenyl)-acetamide 
• 54469-58-8 (4-benzothiazol-2-yl-thiazol-2-yl)-(4-chloro-phenyl)-amine 
• 33856-03-0 3?(2?((4?chlorophenyl)amino)thiazol?4?yl)?2H?chromen?2?one 
• 54819-58-8 2-[2-(4-chloro-anilino)-4-oxo-4,5-dihydro-thiazol-5-yl]-N-(4-nitro-phenyl)-acetamide 
• 2953-89-1 (4-chloro-phenyl)-(4,6,6-trimethyl-6H-[1,3]thiazin-2-yl)-amine 
• 63082-69-9 [3-(4-chloro-anilino)-4-phenyl-4H-[1,2,4]thiadiazol-5-ylidene]-phenyl-amine 
• 31102-89-3 7-chloro-3-(4-chloro-phenyl)-3H-thiazolo[4,5-b]quinoxalin-2-ylideneamine 

Relevant academic research and scientific papers

Design, synthesis, and antipoliferative activities of novel substituted imidazole-thione linked benzotriazole derivatives

A new series of benzotriazole moiety bearing substituted imidazol-2-thiones at N1 has been designed, synthesized and evaluated for in vitro anticancer activity against the different cancer cell lines MCF-7(breast cancer), HL-60 (Human promyelocytic leukemia), and HCT-116 (colon cancer). Most of the benzotriazole analogues exhibited promising antiproliferative activity against tested cancer cell lines. Among all the synthesized compounds, BI9 showed potent activity against the cancer cell lines such as MCF-7, HL-60 and HCT-116 with IC50 3.57, 0.40 and 2.63 μM, respectively. Compound BI9 was taken up for elaborate biological studies and the HL-60 cells in the cell cycle were arrested in G2/M phase. Compound BI9 showed remarkable inhibition of tubulin polymerization with the colchicine binding site of tubulin. In addition, compound BI9 promoted apoptosis by regulating the expression of pro-apoptotic protein BAX and anti-apoptotic proteins Bcl-2. These results provide guidance for further rational development of potent tubulin polymerization inhibitors for the treatment of cancer.

Green and efficient synthesis of thioureas, ureas, primary: O -thiocarbamates, and carbamates in deep eutectic solvent/catalyst systems using thiourea and urea

An efficient and general catalysis process was developed for the direct preparation of various primary O-thiocarbamates/carbamates as well as monosubstituted thioureas/ureas by using thiourea/urea as biocompatible thiocarbonyl (carbonyl) sources. This procedure used choline chloride/tin(ii) chloride [ChCl][SnCl2]2 with a dual role as a green catalyst and reaction medium to afford the desired products in moderate to excellent yields. Moreover, the DES can be easily recovered and reused for seven cycles with no significant loss in its activity. Besides, the method shows very good performance for synthesizing the desired products on a large scale.

Synthesis and biological evaluation of 3-amino-1,2,4-triazole derivatives as potential anticancer compounds

Two series of compounds carrying 3-amino-1,2,4-triazole scaffold were synthesized and evaluated for their anticancer activity against a panel of cancer cell lines using XTT assay. The 1,2,4-triazole synthesis was revisited for the first series of pyridyl derivatives. The biological results revealed the efficiency of the 3-amino-1,2,4-triazole core that could not be replaced and a clear beneficial effect of a 3-bromophenylamino moiety in position 3 of the triazole for both series (compounds 2.6 and 4.6) on several cell lines tested. Moreover, our results point out an antiangiogenic activity of these compounds. Overall, the 5-aryl-3-phenylamino-1,2,4-triazole structure has promising dual anticancer activity.

Novel compound bassed on thiazolidine and use thererof

The present invention relates to a novel compound and uses thereof. More specifically, the present invention provides: a novel compound based on thiazolidine which can effectively inhibit the aggregation of tau, one of the causes of Alzheimerandprime;s disease; and uses thereof. According to the novel compound and uses thereof composed as described above, it is possible to realize an effect of producing a therapeutic agent for Alzheimerandprime;s dementia due to tau aggregation.COPYRIGHT KIPO 2020

Synthetic (E)-3-phenyl-5-(phenylamino)-2-styryl-1,3,4-thiadiazol-3-ium chloride derivatives as promising chemotherapy agents on cell lines infected with HTLV-1

Synthesis of four compounds belonging to mesoionic class, (E)-3-phenyl-5-(phenylamino)-2-styryl-1,3,4-thiadiazol-3-ium chloride derivatives (5a-d) and their biological evaluation against MT2 and C92 cell lines infected with human T-cell lymphotropic virus type-1 (HTLV-1), which causes adult T-cell leukemia/lymphoma (ATLL), and non-infected cell lines (Jurkat) are reported. The compounds were obtained by convergent synthesis under microwave irradiation and the cytotoxicity was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Results showed IC50 values of all compounds in the range of 1.51-7.70 μM in HTLV-1-infected and non-infected cells. Furthermore, it was observed that 5b could induce necrosis after 24 h for Jurkat and MT2 cell lines. The experimental (fluorimetric method) and theoretical (molecular docking) results suggested that the mechanism of action for 5b could be related to its capacity to intercalate into DNA. Moreover, the preliminary pharmacokinetic profile of the studied compounds (5a-d) was obtained through human serum albumin (HSA) binding affinity using multiple spectroscopic techniques (circular dichroism, steady-state and time-resolved fluorescence), zeta potential and molecular docking calculations. The interaction HSA:5a-d is spontaneous and moderate (Ka ～ 104 M-1) via a ground-state association, without significantly perturbing both the secondary and surface structures of the albumin in the subdomain IIA (site I), indicating feasible biodistribution in the human bloodstream.

Synthesis of Novel Triazole Incorporated Thiazolone Motifs Having Promising Antityrosinase Activity through Green Nanocatalyst CuI-Fe3O4@SiO2 (TMS-EDTA)

In the present work, novel 5-((1-benzyl-1,2,3-triazol-4-yl)methoxybenzylidene)-2-(arylamino)thiazol-4-one thiazolone incorporated triazole derivatives have been designed as tyrosinase inhibitors. The compounds were synthesized through click reaction in good yield. Moreover, the antityrosinas activity of the synthesized derivatives was evaluated. In the search for establishing a click copper-catalyzed azide/alkyne cycloaddition (CuAAC) reaction under strict conditions, in terms of a novel air-stable, a recyclable and efficient magnetic catalyst was planned for new triazole derivatives as a well-organized copper iodide supported on the functionalized Fe3O4@SiO2 core-shell (CuI/Fe3O4@SiO2(TMS-EDTA) nanoparticles). The engineered nanocatalyst synthesized for the first time and characterized by different methods, including FT-IR spectroscopy, XRD, FESEM, EDX, TEM, TGA, and BET analysis. The excellent catalytic performance in ethanol with high surface area (351.7 m2g?1) and short reaction time for diverse functional groups (120–200 min), no use of toxic solvents, reusability of the catalyst, and using eco-friendly conditions are the advantageous of this work. Moreover,the nanocatalyst can be used at least five times without any significant decrease in the yield of the reaction. The thiazolidine-triazole derivatives 9a, 9c, 9e, and 9 g showed promising tyrosinase inhibitory activity with IC50 values in the range of 5.90–9.81 μM. The compounds were found to be considerably more potent tyrosinase inhibitors than the reference inhibitor kojic acid (IC50 = 18.36 μM).

Identification of: N -benzothiazolyl-2-benzenesulfonamides as novel ABCA1 expression upregulators

ATP binding cassette transporter A1 (ABCA1) is a critical transporter that mediates cellular cholesterol efflux from macrophages to apolipoprotein A-I (ApoA-I). Therefore, increasing the expression level of ABCA1 is anti-atherogenic and ABCA1 expression upregulators have become novel choices for atherosclerosis treatment. In this study, a series of N-benzothiazolyl-2-benzenesulfonamides, based on the structure of WY06 discovered in our laboratory, were designed and synthesized as novel ABCA1 expression upregulators. Based on an in vitro ABCA1 upregulatory cell model, ABCA1 upregulation of target compounds was evaluated. Compounds 6c, 6d, and 6i have good upregulated ABCA1 expression activities, with EC50 values of 0.97, 0.37, and 0.41 ΜM, respectively. A preliminary structure-activity relationship is summarized. Replacing the methoxy group on the benzothiazole moiety of WY06 with a fluorine or chlorine atom and exchanging the ester group with a cyano group resulted in more potent ABCA1 upregulating activity. Moreover, compound 6i increased ABCA1 mRNA and protein expression and significantly promoted cholesterol efflux in RAW264.7 cells. In conclusion, N-benzothiazolyl-2-benzenesulfonamides were identified as novel ABCA1 expression upregulators.

Design, synthesis and biological evaluation of novel N,4-diphenylthiazol-2-amine derivatives

Novel N,4-diphenylthiazol-2-amine derivatives were designed and synthesized employing Hantzsch method. The three-step reaction involved in the synthesis occurred at a faster rate with excellent yields in eco-friendly conditions. The synthesized derivatives were characterized by spectral techniques such as 1H NMR, 13C NMR, FT-IR and GCMS. Single-crystal X-ray diffraction studies also confirmed the formation of title compounds. These compounds were evaluated in vitro for their antimicrobial and anti-inflammatory activities. The results demonstrated that most of the tested compounds showed potent antifungal activity. Interestingly, these compounds also exhibited good anti-inflammatory and moderate antibacterial activity towards sensitive as well as resistant bacterial strains. In silico studies depicted their good binding affinity profile against S. aureus (PDB ID: 1AD4) and C. albicans (PDB ID: 1AI9). [Figure not available: see fulltext.].

Disrupting the Conserved Salt Bridge in the Trimerization of Influenza A Nucleoprotein

Antiviral drug resistance in influenza infections has been a major threat to public health. To develop a broad-spectrum inhibitor of influenza to combat the problem of drug resistance, we previously identified the highly conserved E339?R416 salt bridge of the nucleoprotein trimer as a target and compound 1 as an inhibitor disrupting the salt bridge with an EC50 = 2.7 μM against influenza A (A/WSN/1933). We have further modified this compound via a structure-based approach and performed antiviral activity screening to identify compounds 29 and 30 with EC50 values of 110 and 120 nM, respectively, and without measurable host cell cytotoxicity. Compared to the clinically used neuraminidase inhibitors, these two compounds showed better activity profiles against drug-resistant influenza A strains, as well as influenza B, and improved survival of influenza-infected mice.

CuBr2 mediated synthesis of 2-Aminothiazoles from dithiocarbamic acid salts and ketones

In a one-pot procedure, CuBr2 has been used as a efficient desulfurizing agent in the synthesis of 2-aminothiazoles by the condensation of in situ-generated 1-substituted thioureas from their dithiocarbamic acid salts, with in situ-generated α-bromoketones from ketones. All reactions were carried out under optimized reaction conditions and gave the target products in 61–95% yield.